Neonc Technologies Holdings Inc (NTHI) Stock Price, Quote & News

Company Profile

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, h...

Industry: Biotechnology

Sector: Healthcare

Phone: 310 663 7831

Website: www.neonc.com

Address:

23975 Park Sorrento, Suite 205, Calabasas, United States

FrostReaper May. 31 at 9:23 PM

$NTHI Multiple Phase 2-stage programs: Phase IIa work underway for NEO100. Phase I/II development for NEO212.

0 · Reply

FrostReaper May. 31 at 9:16 PM

$NTHI Focused on high-need brain cancer markets. NeOnc is developing: NEO100 for recurrent high-grade gliomas and glioblastoma…

0 · Reply

NeOnc_Technologies May. 24 at 8:34 AM

$NTHI We invite shareholders to take a closer look at one of the key financial takeaways from NeOnc’s Q1 2026 update: Approximately 31% of the company’s Q1 2026 net loss was related to non-cash stock-based compensation, resulting in normalized cash operating expenses of approximately $6.1 million for the quarter (~$24.4 million annualized). At the same time, NeOnc continued advancing both lead CNS oncology programs, including: • NEO212 advancing toward potential registrational Phase 2 discussions with the FDA • NEO100 Phase 2a remaining fully enrolled with interim data anticipated later this year The company remains focused on balancing clinical execution with operational discipline as multiple potential catalysts approach in 2026. Full update: https://investors.neonc.com/news-releases/news-release-details/neonc-provides-business-update-and-reports-q1-2026-financial

0 · Reply

OmidArefi May. 20 at 8:49 AM

$NTHI 👀

0 · Reply

NeOnc_Technologies May. 20 at 8:04 AM

NeOnc Technologies Holdings, Inc. ($NTHI) received new analyst coverage from Maxim Group, which initiated coverage with a Buy rating and a $20 price target. The report highlights NeOnc’s blood-brain barrier bypassing platform for high-grade gliomas, with two core clinical opportunities: NEO100 as a near-term value driver and NEO212 as a significant earlier-stage opportunity. Key points noted in the report include: • NEO100: Intranasal perillyl alcohol formulation designed for direct nose-to-brain delivery, with Phase 2a top-line data expected in 2H 2026 • NEO212: Oral bioconjugate of NEO100 and temozolomide for recurrent GBM, with prior data suggesting approximately 3x higher brain exposure vs. TMZ • NEO212 next step: Type B meeting to align on Phase 2 study design • Financial position: Maxim notes access to a $75M ATM and $10M line of credit Read more here: https://maxim.bluematrix.com/sellside/EmailDocViewer?encrypt=b7f7c799-8752-4d27-b873-4419a21894f5&mime=pdf&co=maxim&[email protected]&source=mail

0 · Reply

NeOnc_Technologies May. 19 at 3:05 PM

NeOnc Technologies (Nasdaq: $NTHI) is proud to share Q1 2026 financial results and provide a business update highlighting continued progress across both of our clinical-stage CNS oncology programs. Key highlights from the quarter include: • Completion of the Phase 1 dose-escalation portion of NEO212, with 610 mg established as the recommended Phase 2 dose • Continued advancement of the fully enrolled NEO100 Phase 2a study, with interim data expected around August 2026 • Significant year-over-year improvement in financial performance, with Q1 2026 net loss reduced to $8.8M versus $32.3M in Q1 2025 • Ongoing preparation for a Type B End-of-Phase 1 FDA meeting for NEO212 “Our focus remains on disciplined execution as we advance both programs toward important regulatory and clinical milestones,” said Amir Heshmatpour, CEO, Executive Chairman, and President. Read the full announcement here: https://investors.neonc.com/news-releases/news-release-details/neonc-provides-business-update-and-reports-q1-2026-financial

0 · Reply

focafoca99 May. 19 at 3:01 PM

$NTHI receives growing analyst coverage and insider buying as it nears key brain‑cancer trial milestones.

0 · Reply

focafoca99 May. 18 at 9:23 PM

$NTHI released its first-quarter 2026 financial results.

0 · Reply

NeOnc_Technologies May. 17 at 9:28 AM

A quote from Amir Heshmatpour, Chief Executive Officer, Executive Chairman, and President of NeOnc Technologies, following the Company’s recent announcement regarding continued insider buying and a $500K+ personal investment ahead of upcoming NEO100 Phase 2a data catalysts. $NTHI

0 · Reply

BOUDIN420 May. 16 at 6:41 PM

$NTHI

0 · Reply

The Next Great AI Revolution May Be Drug Delivery

May 19, 2026, 10:28 AM EDT - 14 days ago

NeOnc Technologies Gains Growing Institutional Support Ahead of Key Brain Cancer Clinical Milestones

2026-05-19T11:05:51.000Z - 14 days ago

NeOnc Technologies initiated with a Buy at Alliance Global

May 18, 2026, 9:00 AM EDT - 15 days ago

NeOnc Provides Business Update and Reports Q1 2026 Financial Results

2026-05-18T12:00:00.000Z - 15 days ago

NeOnc Technologies initiated with a Buy at Maxim

May 7, 2026, 8:45 AM EDT - 26 days ago

Biotech's Next Wave May Already be in Motion

May 6, 2026, 8:35 AM EDT - 27 days ago

Where Executives Are Doubling Down on Their Companies' Fortunes

May 5, 2026, 9:00 AM EDT - 4 weeks ago

NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts

2026-04-24T10:17:12.000Z - 5 weeks ago

NeOnc Technologies initiated with a Buy at BTIG

2026-04-10T21:20:42.000Z - 7 weeks ago

NeOnc Technologies files to sell 680,558 shares of common stock for holders

2026-04-02T17:07:18.000Z - 2 months ago

NeOnc Technologies files $300M mixed securities shelf

Apr 1, 2026, 9:00 AM EDT - 2 months ago

NeOnc Provides Business Update and Reports Q4 2025 Financial Results

2026-03-13T13:05:36.000Z - 2 months ago

NeOnc Technologies appoints Choi as Chief Accounting Officer

Mar 13, 2026, 9:00 AM EDT - 2 months ago

NeOnc Technologies Appoints David Choi as Chief Accounting Officer

Mar 12, 2026, 8:52 AM EDT - 2 months ago

Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)

2026-03-04T13:06:31.000Z - 3 months ago

NeOnc Technologies reports Phase 1 dose-escalation results for NEO212

Mar 4, 2026, 8:00 AM EST - 3 months ago

NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET

MRK

Feb 27, 2026, 9:00 AM EST - 3 months ago

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and Toxicity

2026-02-06T21:55:14.000Z - 4 months ago

NeOnc Technologies files to sell 2.95M shares of common stock for holders

2026-01-30T14:17:11.000Z - 4 months ago

NeOnc Technologies secures strategic PIPE investment from Cinctive Capital

Jan 30, 2026, 9:00 AM EST - 4 months ago

NeOnc Technologies Secures Strategic PIPE Investment led by $10 Million Investment from Cinctive Capital Management

Jan 9, 2026, 7:32 PM EST - 5 months ago

Stonegate Capital Partners Initiates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)

2025-12-15T14:16:09.000Z - 6 months ago

NeOnc Technologies announces updated NEO100 clinical results

Dec 15, 2025, 9:00 AM EST - 6 months ago

NeOnc Technologies Reports Updated Clinical Results

2025-12-15T13:00:48.000Z - 6 months ago

NeOnc Technologies files to sell 111.7K shares of common stock for holders

2025-12-01T14:10:42.000Z - 6 months ago

NeOnc Technologies announces preclinical findings from USC collaboration

Dec 1, 2025, 9:00 AM EST - 6 months ago

NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors

2025-11-13T14:16:23.000Z - 7 months ago

NeOnc Technologies completes full patient enrollment in NEO100-1 Phase 2a trial

Nov 13, 2025, 9:00 AM EST - 7 months ago

NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High‑Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026)

2025-11-12T13:26:29.000Z - 7 months ago

NeOnc announces updated results Phase 1/2a, compassionate care studies

Nov 7, 2025, 9:00 AM EST - 7 months ago

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program

2025-11-04T14:05:59.000Z - 7 months ago

NeOnc Technologies appoints Heshmatpour as Chief Executive Officer

2025-10-28T13:10:14.000Z - 7 months ago

NeOnc says Sheikh Nahyan bin Zayed Al Nahyan assumes NuroMENA chairmanship

2025-10-09T13:10:30.000Z - 8 months ago

NeOnc Technologies’ NuroMENA signs master services agreement with M42’s IROS

Oct 9, 2025, 9:00 AM EDT - 8 months ago

NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42's IROS and Expands Board of Directors

2025-10-06T13:10:28.000Z - 8 months ago

NeOnc Technologies, Quazar Investment to close $50M partnership by Oct. 23

2025-10-02T13:05:51.000Z - 8 months ago

NeOnc Technologies appoints David Ashley to Scientific Advisory Board

Sep 29, 2025, 9:00 AM EDT - 8 months ago

NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board

Sep 10, 2025, 9:40 AM EDT - 9 months ago

Blue Gold Appoints Quazar's Sameer Salgar to Advisory Board to Establish UAE Ties and Guide Digital Gold Strategy

BGL

Sep 10, 2025, 9:00 AM EDT - 9 months ago

NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer

Aug 25, 2025, 9:00 AM EDT - 10 months ago

NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board

Aug 11, 2025, 9:00 AM EDT - 10 months ago

NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation

Aug 7, 2025, 9:00 AM EDT - 10 months ago

NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia

Aug 4, 2025, 9:00 AM EDT - 10 months ago

NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer

Jul 30, 2025, 9:00 AM EDT - 10 months ago

NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors

Jul 23, 2025, 10:53 AM EDT - 11 months ago

CORRECTING and REPLACING - NeOnc Technologies Holdings, Inc.

Jul 8, 2025, 9:00 AM EDT - 11 months ago

NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform

Jun 6, 2025, 9:00 AM EDT - 1 year ago

NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs

Apr 15, 2025, 8:05 AM EDT - 1 year ago

NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets

Apr 14, 2025, 8:05 AM EDT - 1 year ago

NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September

Apr 10, 2025, 8:05 AM EDT - 1 year ago

NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President

Apr 8, 2025, 4:05 PM EDT - 1 year ago

NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy

Mar 31, 2025, 8:05 AM EDT - 1 year ago

NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas

Mar 27, 2025, 8:05 AM EDT - 1 year ago

NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments

Mar 25, 2025, 8:45 AM EDT - 1 year ago

NeOnc Technologies Appointments the Honorable Jimmy Delshad to its Board of Directors

Mar 25, 2025, 8:15 AM EDT - 1 year ago

NEONC Technologies Holdings, Inc. Appoints Renowned Neurosurgeon Dr. Steven L. Giannotta to its Board of Directors

Oct 7, 2024, 11:00 AM EDT - 1 year ago

NeOnc Technologies Receives Pharma Tech Outlook's Top Drug Delivery Platform Award for 2024

Aug 5, 2024, 11:00 AM EDT - 1 year ago

NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted with Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate

Jul 16, 2024, 11:15 AM EDT - 2 years ago

NeOnc Technologies Receives FDA Approval to Expand NEO100-01™ Phase 2a Clinical Trial to Include Patients with Recurrent Grade III Astrocytoma Brain Tumors Exhibiting IDH1 Mutation

Jun 26, 2024, 4:39 PM EDT - 2 years ago

NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status

May 15, 2024, 11:00 AM EDT - 2 years ago

NeOnc Technologies Wins California Investment Forum's Breakthrough Medical Technology Achievement Award

May 9, 2024, 5:30 PM EDT - 2 years ago

NeOnc Technologies Invited to Present at California Investment Forum in Anaheim on May 10

FrostReaper May. 31 at 9:23 PM

$NTHI Multiple Phase 2-stage programs: Phase IIa work underway for NEO100. Phase I/II development for NEO212.

0 · Reply

FrostReaper May. 31 at 9:16 PM

$NTHI Focused on high-need brain cancer markets. NeOnc is developing: NEO100 for recurrent high-grade gliomas and glioblastoma…

0 · Reply

NeOnc_Technologies May. 24 at 8:34 AM

0 · Reply

OmidArefi May. 20 at 8:49 AM

$NTHI 👀

0 · Reply

NeOnc_Technologies May. 20 at 8:04 AM

0 · Reply

NeOnc_Technologies May. 19 at 3:05 PM

0 · Reply

focafoca99 May. 19 at 3:01 PM

$NTHI receives growing analyst coverage and insider buying as it nears key brain‑cancer trial milestones.

0 · Reply

focafoca99 May. 18 at 9:23 PM

$NTHI released its first-quarter 2026 financial results.

0 · Reply

NeOnc_Technologies May. 17 at 9:28 AM

0 · Reply

BOUDIN420 May. 16 at 6:41 PM

$NTHI

0 · Reply

NeOnc_Technologies May. 13 at 11:51 AM

$NTHI NeOnc Technologies is proud to announce that CEO, Executive Chairman, and President Amir Heshmatpour has continued to increase his personal ownership in the Company through open-market stock purchases, investing more than $500,000 in recent weeks and nearly $1 million over the past year. All purchases were made with personal funds and disclosed through SEC Form 4 filings. The continued insider buying comes as NeOnc advances key clinical and regulatory milestones, including: • Fully enrolled Phase 2a study of NEO100 in recurrent IDH1-mutant high-grade glioma • Interim NEO100 data analysis expected later in 2026 • Completion of NEO212 Phase 1 dose escalation with recommended Phase 2 dose established Read more: https://investors.neonc.com/news-releases/news-release-details/neonc-ceo-accelerates-insider-buying-500k-investment-ahead

0 · Reply

banner20 May. 12 at 3:21 PM

$NTHI there will probably be another offering straight after read out here

0 · Reply

SuperGreenToday May. 6 at 2:45 PM

$NTHI

0 · Reply

Bigmal1 May. 6 at 1:24 PM

$NTHI yo the ask this pre market is bonkers!!

0 · Reply

LewisDaKat May. 5 at 7:30 PM

$NTHI NeOnc CEO Doubles Down with Insider Conviction Ahead of Critical Brain Cancer Data https://marketwirenews.com/stock/nthi/news/neonc-ceo-doubles-down-with-insider-conviction-ahead-8093992041761237.html?utm_source=stocktwits

0 · Reply

RETAlerts May. 5 at 3:28 PM

Tight float on $NTHI means less shares to move price. Up 6.8% shows what happens when volume hits a small float. Amplification ...

0 · Reply

DARKP00L May. 5 at 1:07 PM

$NTHI 09:03 on May. 05 2026 NeOnc Technologies Says CEO, Executive Chairman, And President Amir Heshmatpour Increases Personal Ownership Through Consistent Open-Market Purchases #tradeideas

0 · Reply

NeOnc_Technologies May. 5 at 9:28 AM

NeOnc Technologies continues to gain momentum. BTIG has initiated coverage with a Buy rating and a $15 PT, led by analyst Thomas Shrader. A strong vote of confidence as we advance innovative therapies for CNS cancers. $NTHI #Biotech #BTIG #BuyRating https://investors.neonc.com/static-files/3367906a-207c-4d88-adec-9422975ff754

0 · Reply

topstockalerts May. 3 at 1:03 PM

After Hours Top Gainers PT2 $CELC $EBAY $NTHI $BNKK $DMRC

0 · Reply

topstockalerts May. 2 at 10:05 AM

After Hours Top Gainers PT2 $CELC $EBAY $NTHI $BNKK $DMRC

0 · Reply

vestenius Apr. 30 at 8:14 PM

$NTHI entry

0 · Reply

SocioCobb Apr. 28 at 11:25 PM

$NTHI

0 · Reply

Market Cap	N/A
Revenue (ttm)	N/A
Net Income (ttm)	N/A
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	9,700
Avg Vol	N/A
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	N/A
Beta	N/A
Analysts	N/A
Price Target	N/A